Personal KinetiGraph® Clinical Validation Study

Last updated: October 9, 2025
Sponsor: Global Kinetics Corporation
Overall Status: Completed

Phase

N/A

Condition

Dystonias

Tardive Dyskinesia

Dyskinesias

Treatment

Personal KinetiGraph® (PKG®) System

Clinical Study ID

NCT05251701
Study 006
  • Ages > 18
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

The purpose of this study is to clinically validate new measures of the Personal KinetiGraph® (PKG®).

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Able and willing to sign a written informed consent for study participation

  • Existing diagnosis of a movement disorder or a healthy control subject withoutdiagnosis of a movement disorder

Exclusion

Exclusion Criteria:

  • Bedridden, wheelchair confined, or requires the regular use of an assistive gaitdevice (e.g., walker, cane, etc.)

  • Occupation that involves repetitive movement or complete immobility (e.g., janitor,construction, or sedentary with no/limited arm movements such as a taxi driver)

  • In the investigator's or sponsor's opinion, subject has any unstable or clinicallysignificant condition that would impair the participant's ability to complete therequired PKG watch wear (e.g., subject unable to complete PKG wear instructions perPatient Instruction Manual), complete required assessments or interfere with datacollection.

Study Design

Total Participants: 19
Treatment Group(s): 1
Primary Treatment: Personal KinetiGraph® (PKG®) System
Phase:
Study Start date:
December 09, 2022
Estimated Completion Date:
September 03, 2025

Study Description

This is a prospective, observational research study of the Personal KinetiGraph (PKG) System. The PKG System is intended to quantify kinematics of movement disorder symptoms in conditions such as Parkinson's disease, including tremor, bradykinesia and dyskinesia. This study aims to clinically validate new PKG assessments such as walking, Device Assisted Therapy readiness, Percent Time Bradykinesia, Percent Time Dyskinesia, fall prediction, disease progression and non-motor. The clinical validation will require enrollment of both subjects with a diagnosis of movement disorder, such as Parkinson's disease, and healthy control subjects who do not a neurological disorder.

Connect with a study center

  • Tucson Neuroscience Research

    Tucson, Arizona 85710
    United States

    Site Not Available

  • Tucson Neuroscience Research

    Tucson 5318313, Arizona 5551752 85710
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.